

ORIGINAL ARTICLE

Overexpression of caspase 7 is ER α dependent to affect proliferation and cell growth in breast cancer cells by targeting p21^{Cip}S Chaudhary¹, B Madhukrishna¹, AK Adhya², S Keshari¹ and SK Mishra¹

Caspase 7 (*CASP7*) expression has important function during cell cycle progression and cell growth in certain cancer cells and is also involved in the development and differentiation of dental tissues. However, the function of *CASP7* in breast cancer cells is unclear. The aim of this study was to analyze the expression of *CASP7* in breast carcinoma patients and determine the role of *CASP7* in regulating tumorigenicity in breast cancer cells. In this study, we show that the *CASP7* expression is high in breast carcinoma tissues compared with normal counterpart. The ectopic expression of *CASP7* is significantly associated with ER α expression status and persistently elevated in different stages of the breast tumor grades. High level of *CASP7* expression showed better prognosis in breast cancer patients with systemic endocrine therapy as observed from Kaplan–Meier analysis. S3 and S4, estrogen responsive element (ERE) in the *CASP7* promoter, is important for estrogen-ER α -mediated *CASP7* overexpression. Increased recruitment of p300, acetylated H3 and pol II in the ERE region of *CASP7* promoter is observed after hormone stimulation. Ectopic expression of *CASP7* in breast cancer cells results in cell growth and proliferation inhibition via p21^{Cip} reduction, whereas small interfering RNA (siRNA) mediated reduction of *CASP7* rescued p21^{Cip} levels. We also show that pro- and active forms of *CASP7* is located in the nucleus apart from cytoplasmic region of breast cancer cells. The proliferation and growth of breast cancer cells is significantly reduced by broad-spectrum peptide inhibitors and siRNA of *CASP7*. Taken together, our findings show that *CASP7* is aberrantly expressed in breast cancer and contributes to cell growth and proliferation by downregulating p21^{Cip} protein, suggesting that targeting *CASP7*-positive breast cancer could be one of the potential therapeutic strategies.

Oncogenesis (2016) 5, e219; doi:10.1038/oncsis.2016.12; published online 18 April 2016

INTRODUCTION

Breast cancer (BC) is a common form of cancer in women with an incidence of 232 670 new cases and 40 000 deaths estimated in 2014 in US alone (Surveillance, Epidemiology and End Results Program, National Cancer Institute). These incidence rates have declined in Caucasian women who refrained to use post menopausal hormone therapy, but have slightly risen in Afro-American cohorts. Early stages of BC development are facilitated by signals or inducers like estrogen (E2) that can orient the cells to either proliferate or differentiate.^{1,2} Therefore, a detailed understanding and novel facets of E2 signaling may present a target for therapeutic advantage.

Majority of the BC are estrogen receptor alpha (ER α) positive, which accounts for ~60–70% of the breast cancer cases;^{3,4} ~50% of the ER-positive BCs are estrogen dependent and responded to endocrine therapy such as tamoxifen.^{5–7} E2 acts through ER α and estrogen receptor beta (ER β) has a pivotal role in mammary gland development and morphogenesis.⁸ E2-activated ER α regulate proliferation by regulating several cell cycle genes such as *c-Myc*, *cyclin D1*, *cyclin E*, *A*, *Cdc25A*, *p45Skip2* and *p27Kip1*.⁹ In addition, overexpression of ER α induces G1/S cell cycle transition by inducing *cyclin D1* and *c-Myc*¹⁰ and subsequent reduction of cyclin-dependent kinase inhibitors p21^{Cip} and p27^{Kip1}¹¹ to contribute proliferation and cell growth. Other ERs such as Orphan

ERs share sequence homology and cross-talk between them induces varied cellular response.^{12,13}

Caspase 7 (*CASP7*) encodes a cysteine protease enzyme that is associated with apoptosis and inflammation.^{14,15} *CASP7* is proposed to be redundant to caspase 3 (*CASP3*) that has a major role in the execution of apoptosis.^{16,17} However, recent studies have reported that *CASP7* function to regulate cell cycle progression and differentiation of certain cell types.^{18–21} Caspases are activated in cascades. Caspase 2, 8, 9, 10 (*CASP2*, 8, 9, 10) termed as initiator caspases are the large pro-domain caspases, cleave the short pro-domain caspases—caspase 3 (*CASP3*), 6 (*CASP6*) and 7 also known as effector caspases. Activated caspases have been detected in different model systems in a non-apoptotic manner.^{18,19,22,23} Elevated levels of *CASP7* have been reported to be associated with moderate and well-differentiated tumors in OSCC.²⁴ As *CASP7* was essential for proliferation and cell growth^{18,19} and its expression in primary breast carcinoma showed no correlation with rate of apoptosis;²² we hypothesize that *CASP7* may mediate some non-apoptotic function-like cell proliferation in the breast cancer cells. Our studies show that *CASP7* is overexpressed in breast carcinoma and correlated with ER α status of the disease. We also demonstrated that overexpression of *CASP7* downregulated p21^{Cip} at the protein level and inhibition of *CASP7* by broad-spectrum peptide inhibitors and

¹Cancer Biology Laboratory, Gene Function and Regulation group, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Odisha, India and ²Department of Pathology, Kalinga Institute of Medical Sciences, KIIT Rd, Chandaka Industrial Estate, Patia, Bhubaneswar, Odisha, India. Correspondence: Dr SK Mishra, Cancer Biology Laboratory, Gene Function and Regulation group, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751023, Odisha, India. E-mail: sandipkmishra@hotmail.com

Received 25 May 2015; revised 1 December 2015; accepted 17 December 2015

small interfering RNA (siRNA) reduced the proliferation and growth of breast cancer cells.

RESULTS

Aberrant *CASP7* expression in primary breast carcinoma and cell lines

To determine the relationship between *CASP7* expression and breast carcinogenesis we compared the expression of *CASP7* in normal and breast carcinoma tissues from the data obtained from Oncomine (<https://www.oncomine.org>). In total, 10 of the 12 data sets that contained gene expression profile of normal and breast carcinoma tissues showed elevated *CASP7* mRNA levels in primary breast carcinomas than in normal breast tissues with certain variations. The representatives of three independent data with significant *CASP7* expression were shown in Figure 1a (Finak *et al.*,²⁵ $P=5.30E-19$, Ma *et al.*,²⁶ $P=0.015$, Richardson *et al.*,²⁷ $P=0.041$).²⁵⁻²⁷ Western blot result shows high *CASP7* expression levels in MCF7 and T47D breast cancer cells compared with noncancerous breast cell line, MCF10A (Figure 1b), higher in MCF7 and T47D than MDA-MB231. These results show that *CASP7* is overexpressed in breast carcinoma patients and ER α -positive breast cancer cells.

CASP7 expression is consistently elevated in different breast tumor grades and ER α dependent

To assess the role of *CASP7* expression in breast carcinogenesis, we analyzed commercially available tissue microarray (TMA) slide consisting of 75 breast invasive ductal carcinoma samples of different stages. Of these 75 samples, 32 (42.66%) were negative and 43 (57.34%) were positive for *CASP7* staining (Table 1). Analysis by grades showed no correlation with *CASP7* expression; however, a consistent high level of *CASP7* expression was observed in different stages of the breast carcinoma (Figure 2a,

Table 1). Similarly, the *CASP7* expression was analyzed in Oncomine data sets where the breast carcinomas were grouped according to different stages of the disease. Finak *et al.*²⁵ and Ma *et al.*²⁶ data sets indicated a significant upregulation of *CASP7* mRNA in different grades of breast carcinoma (Figure 2b). In addition, a significant correlation between *CASP7* mRNA expression and ER α positivity in breast carcinoma tissues of Chin *et al.*²⁸ and Minn *et al.*²⁹ data sets was observed (Figure 2c). TMA analyses showed 29% positive and no variation (21% negative, 20% positive) in *CASP7* expression in ER α -positive and -negative breast tumors, respectively (Table 1, Figure 2d). The results were further confirmed in ER α knockdown MCF7 cells, which showed a significant decrease in *CASP7* expression with ER α depletion in the cells (Figure 2e). To further examine the clinicopathological

Table 1. *CASP7* staining in TMA

	<i>CASP7</i> staining	
	Negative	Positive
Patients	32 (42.66%)	43 (57.34%)
<i>Receptor subtype</i>		
ER+/PR+	8 (10.66%)	17 (22.66%)
ER-/PR+	1 (1.33%)	0
ER+/PR-	2 (2.66%)	5 (6.66%)
ER-/PR-	20 (26.66%)	20 (26.66%)
<i>Histological grade</i>		
Grade I	2 (2.66%)	5 (6.66%)
Grade II	25 (33.33%)	31 (41.33%)
Grade III	6 (8%)	6 (8%)

Abbreviations: *CASP7*, caspase 7; ER, estrogen receptor; PR, progesterone receptor; TMA, tissue microarray.




Figure 1. Expression of *CASP7* in normal versus breast carcinoma patients and cell lines. (a) Increased expression of *CASP7* mRNA in breast carcinoma tissues compared with normal breast tissues in three independent Oncomine data sets (Finak *et al.*²⁵; Ma *et al.*²⁶; Richardson *et al.*²⁷). (b) Elevated expression of *CASP7* in breast cancer cell lines compared with normal breast cell line, MCF10A as demonstrated by western blot.




Figure 2. High levels of CASP7 expression in breast tumor grades and correlation with estrogen receptor status with pathological implication. (a) Representative immunohistochemistry images for CASP7 staining in breast carcinoma tissue microarray (TMA) with various tumor grades as specified. (b) Positive correlation between CASP7 mRNA expression and tumor stages in two independent breast carcinoma data sets extracted from Oncomine (Finak *et al.*²⁵; Ma *et al.*²⁶). (c) Positive correlation between CASP7 expression and estrogen receptor status in two independent data sets (Minn *et al.*²⁹; Chin *et al.*²⁸). (d) Percentage of CASP7 staining in breast carcinoma TMA samples. (e) Western blots showing efficient knockdown of ER α and reduction of CASP7 in MCF7 cells. (f) KM survival curve for relapse-free survival in breast cancer patients following combinatorial endocrine therapy. High expression of CASP7 correlated with better prognosis.

implication of CASP7 expression in the breast cancer patients, a cancer survival analysis was performed using Kaplan–Meier plot (<http://www.kmplot.com/breast/>). High expression of CASP7 showed better relapse-free survival (HR = 0.75 (0.6–0.93), $P = 0.01$) in ER-positive breast cancer patients with combinatorial endocrine therapy (Figure 2f). No prognostic value of CASP7 expression was seen in tamoxifen-treated (Supplementary Figure 1a) and ER-negative (Supplementary Figure 1b) breast cancer patients. These results illustrate for the first time that CASP7 expression has a significant clinical relevance and provide probability to predict relapse-free survival in breast cancer.

CASP7 overexpression is estrogen dependent

As CASP7 expression was found to correlate with ER α , we sought to investigate the role of E2, a ligand of ER α on CASP7 expression. To examine this, ER-positive cell line, MCF7 and ER-negative cell line, MDA-MB231 were treated with 100 nM of E2. E2 treatment after 48 h, western blot analysis showed a significant upregulation of CASP7 in MCF7 cells (~1.9-fold) compared with control cells but had no effect in MDA-MB231 cells (~1.3-fold) (Figure 3a). Tamoxifen (10 μ M) and ICI 182 780 (1 μ M) treatment in MCF7 cells significantly inhibited the E2-induced CASP7 mRNA levels (Figure 3b). To understand whether E2 affects directly, protein synthesis inhibitor, cyclohexamide (CHX, 10 μ g/ml) was added prior to hormone treatment. The CASP7 induction by E2 was irrespective to this treatment, suggesting the effect to be protein synthesis independent. However, treatment with transcription inhibitor, actinomycin D (5 μ M) significantly inhibited E2-induced expression (Figure 3c). These results show that CASP7 expression is E2 stimulated and is not mediated by induced proteins.

Presence of estrogen responsive elements in the CASP7 promoter Next, to understand the E2-mediated upregulation of CASP7 we analyzed the CASP7 promoter. *In silico* analysis of CASP7 promoter demonstrated the presence of five putative estrogen responsive elements (ERE) (S1: – 251/– 264, S2: – 288/– 301, S3: – 328/– 341,




Figure 3. Estrogen regulates CASP7 expression. (a) Western blot showing CASP7 expression in MCF7 and MDA-MB231 cell line under E2 influence (upper panel) and densitometry (lower panel). (b) Quantitative RT-PCR showing CASP7 mRNA expression after treatment with E2 and E2 inhibitors- ICI182,780 and tamoxifen. (c) Quantitative RT-PCR showing CASP7 mRNA expression with protein synthesis and transcription inhibitors, cyclohexamide and actinomycin D, respectively. ** $P < 0.01$. * $P < 0.05$. ns = no significant change.

S4: – 408/– 421, S5: – 542/– 555) upstream of the transcription start site (Figure 4a). Previously established CASP7 promoter,³⁰ a kind gift from Professor Srikumar P Chellappan (H Lee Moffitt Cancer Center and Research Institute, FL, USA) and a 622 base pair (–622/+1) CASP7 promoter subcloned into pGL3 luciferase vector




Figure 4. ER α classically regulates *CASP7* promoter. **(a)** Schematic diagram of *CASP7* promoter (upper panel) and putative ER α -binding sites (lower panel). **(b)** Relative luciferase activities after co-transfecting *CASP7* promoters (P-2350 & P-622) and *ER α* in MCF7 cells after 48 h. The data shown are the means \pm s.e. of three individual experiments. **(c)** Relative luciferase activities of P-622 construct with ER α co-transfection after hormone and ICI treatments. The data shown are the means \pm s.e. of three individual experiments. **(d)** *In vitro* DNA-protein-binding assay using 30 base pair oligonucleotides containing putative ERE sites of *CASP7* promoter. Cold competition reaction included 50–100-fold molar excess of consensus ERE sequence. ‘-’ and ‘+’ signifies with and without nuclear lysate, respectively. **(e)** *In vivo* DNA-protein-binding assay of ER α in the putative ERE sites present in the *CASP7* promoter in the presence or absence of E2. ** $P < 0.01$ and * $P < 0.05$.




Figure 5. Other estrogen receptors can also regulate *CASP7*. **(a)** Relative luciferase activities of *CASP7* after co-transfecting P-622, ER β and ERR β with subsequent E2 treatment for 24 h. **(b)** *In vivo* binding of ER β and ERR β in the *CASP7* promoter through putative ERE sites with and without E2 treatment (upper panel). Schematic diagram of Chip PCR performed in *CASP7* promoter (lower panel). * $P < 0.05$. ** $P < 0.01$. *** $P < 0.001$.

termed as P-2350 and P-622, respectively, were subjected to dual luciferase assay after 48 h of co-transfecting the promoter constructs with *ER α* (gift from Professor Ratna K Vadlamudi, University of Texas Health Science Center, San Antonio, TX, USA) in MCF7 cells. E2 significantly upregulated the luciferase activities of P-2350 and P-622 by approximately four and ~2.6-fold, respectively, compared with untreated cells (Figure 4b). However, the luciferase activity of P-622 was ~1.5-fold higher than P-2350 construct during *ER α* co-transfection and hormone stimulation

(Figure 4b). Therefore, P-622 construct was used for further luciferase experiments. Moreover, the luciferase activity of P-622 was approximately ninefold lower than 3XERE control luciferase construct containing three consensus ERE sites. ICI182,780 significantly reduced the E2-induced *CASP7* luciferase activity (Figure 4c).

To test the binding of ER α to the putative ERE sequences, we performed electrophoretic mobility shift assay with oligonucleotides containing putative EREs using nuclear extract from MCF7

cells. The electrophoretic mobility shift assay oligonucleotides containing ERE elements were named as E1 (-244/-276 for S1), E2 (-281/-311 for S2), E3 (-325/-354 for S3), E4 (-399/-429 for

S4) and E5 (-534/-564 for S5). The nuclear protein formed complexes with all the radiolabelled double-stranded oligonucleotides (Figure 4d). The complexes were completely abolished with




Figure 6. Site 3 and 4 are major response element for E2-mediated *CASP7* transcription. (a) Schematic diagram of *CASP7* deletion constructs. (b) The relative luciferase activity of different deletion constructs of *CASP7* after post co-transfecting with *ER α* and E2 treatment for 48 h. The data shown are the means \pm s.e. of three individual experiments. * P < 0.05. *** P < 0.001. ns = no significant change.




Figure 7. Epigenetic factors positively regulate *CASP7* transcription. (a) Western blot of different HDACs and acetylated H3 from whole-cell lysate extracted from MCF7 cells treated with E2 for 48 h. (b) Relative luciferase activities of *CASP7* promoter post co-transfection with *p300*, *p300 Δ HAT* and *ER α* after 24 h of E2 treatment. (c) Recruitment of *p300*, *pol II* and acetylated H3 quantified by Chip PCR in the presence (right panel) or absence (left panel) of E2. * P < 0.05. ** P < 0.01. *** P < 0.001.




Figure 8. CASP7 targets p21^{Cip}. **(a)** Western blot of different cell cycle proteins performed after transfecting CASP7 expression vector in MCF7 and T47D cell lines (left panel). Right panel depicts densitometric analyses of the western blot performed in MCF7 and T47D. **(b)** Western blots performed in whole-cell extract isolated from CASP7 siRNA-transfected MCF7 cells (left panel). Right panel illustrates densitometric analyses of the western blot data. **(c)** MCF7 cells were transfected with CASP7 siRNA (100 pico mole) and vector expressing CASP7. Forty-eight hours later, the expression levels of CASP7 and p21^{Cip} were evaluated by using quantitative RT-PCR. * $P < 0.05$. ** $P < 0.01$. *** $P < 0.001$.

50- or 100-fold molar excess of unlabeled double-stranded ERE consensus sequences. *In vivo* chromatin immunoprecipitation assays (ChIP) assay was performed using antibody specific to ER α in MCF7 cells in the presence or absence of E2. Significant levels of ER α were recruited to the ERE sites during E2 treatment compared with untreated samples (Figure 4e). The PCR product (–232/–419) from immunoprecipitated DNA covered four response elements (S1, S2, S3, S4). Site-specific ChIP PCRs were not performed owing to the close proximity of the response elements and a presence of 40 base pair repeat sequence (–281/–328 and –328/–368) adjacent to each other in the CASP7 promoter. The exact function of this repeat sequence is not known. These data indicate that CASP7 promoter is regulated ‘classically’ by ER α .

Other ERs also regulate CASP7 promoter

As ERs, ER β and ERR β , share sequence homology and recognize ERE to control overlapping pathways,^{12,31,32} we tested the effect of these receptors on CASP7 promoter. The P-622 promoter construct was co-transfected with ER β and ERR β (gift from Professor Ratna K Vadlamudi and Professor Philippa Saunders, MRC Human Reproductive Sciences Unit, UK) with subsequent E2 treatment for 24 h. Dual luciferase assay after 24 h showed a significant P-622 promoter activity with ER β and ERR β co-transfection. Interestingly, ERR β induced luciferase activity of CASP7 was ~1.9-fold greater

than ER β owing to E2 stimulation (Figure 5a). We next evaluated the physical interaction of ER β and ERR β with the CASP7 promoter using ChIP assay. Significantly, the E2 treated MCF7 cells showed increased recruitment of ER β and ERR β compared with untreated control cells (Figure 5b). Taken together, we observed that ER β and ERR β also regulate CASP7 promoter.

Site 3 and 4 is critical in ER α -mediated CASP7 promoter regulation
Next, to identify which of the five ERE elements in the CASP7 promoter was important, different deletion constructs- P-517 (–517/+1, S5 deletion), P-369 (–369/+1, S5 and S4 deletion) and P-197 (–197/+1, all ERE deletion) were co-transfected with ER α in MCF7 cells followed by E2 treatment for 24 h (Figure 6a). S2 and S3 deletion was not possible owing to the presence of 40 base pair repeat sequences adjacent to them. The luciferase activities of P-622 and P-517 were significantly upregulated (P-622, $P < 0.05$ and P-517, $P < 0.05$) as a result of E2 treatment compared with control cells (Figure 6a). Compared with P-517 construct (S5 deletion) the luciferase activity of P-369 construct (S4 and S3 deletion) was significantly reduced ($P < 0.01$). Although a slight nonsignificant elevation of luciferase activity of P-369 was detected with co-transfection and treatment. Taken together, luciferase assays with the deletion constructs suggest S3 and S4 to be important for ER α -mediated CASP7 transactivation.

p300 upregulates *CASP7* promoter activity via acetylating histone H3

Changes in gene expression and protein activities have an important role in cancer initiation and progression, part of which is controlled by histone deacetylases (HDACs) that affect cell growth, differentiation and apoptosis.³³ Therefore, we examined if E2 stimulation had any effect on HDAC expression. We found that E2 stimulation in MCF7 cells did not have any significant effect on the HDAC protein levels (Figure 7a). However, the acetylated histone 3 levels were significantly upregulated during treatment compared with control cells. The acetylation of H3 involves transcriptional coactivator, p300,³⁴ which is a component of ER α coactivator complex.³⁵ Subsequently, p300 (gift from Dr Joan Boyes, Institute of Cancer Research, London, UK) and ER α plasmids were co-transfected with P-622 luciferase construct in MCF7 cells and treated with E2 for 24 h. The *3XERE Luc* was used as a positive control. Significantly, co-transfection of ER α and p300 drastically increased the luciferase activity of P-622. In contrast, significant reduction in P-622 and *3XERE Luc* luciferase activities were observed when wild-type p300 was substituted with histone acetyltransferase domain deleted p300 plasmid (p300 Δ HAT, gift from Dr Joan Boyes), indicating that acetylation of H3 is important

for *CASP7* regulation (Figure 7b). We further determined whether p300 and other factors were enriched in the *CASP7* promoter during treatment by ChIP experiments. ChIP assay showed that p300, pol II and acetylated histone 3 proteins were enriched in the *CASP7* promoter during treatment compared to control cells (Figure 7c). These results show *CASP7* expression is controlled by an ER α coactivator component, p300 by changing acetylated H3 levels.

Overexpression of *CASP7* may regulate cell growth and proliferation via downregulating p21^{CIP}

Earlier reports have demonstrated the non-apoptotic role of *CASP7* targeting various cell cycle inhibitors and DNA repair proteins.^{36,37} Our previous experiments showed the overexpression of *CASP7* in breast carcinomas; therefore, to determine whether *CASP7* affects the cell cycle, we overexpressed *CASP7* (gift from Dr Jean-Bernard Denault, Université de Sherbrooke, Sherbrooke, QC, Canada) in MCF7 and T47D cells and examined the cell cycle proteins by western blot. *CASP7* overexpression was found to significantly reduce the expression of cell cycle inhibitor, p21^{CIP} in both the breast cancer cells (MCF7 ~2.5-fold; T47D ~1.6-fold) (Figure 8a). However, no significant changes were observed




Figure 9. Localization of CASP7 and cleaved CASP7 in the nucleus. (a) TMA of breast carcinoma is stained with CASP7 antibody (ab32522). Arrow mark shows positive staining of CASP7 in the nucleus. (b) Western blot showing localization of CASP7 in the nucleus performed after cell fractionation of MCF7 cells. H3 and α tubulin are used to confirm the fractionation. (c, d) Localization of CASP7 and cleaved CASP7 was determined by indirect immunofluorescence using primary antibodies against CASP7 and cleaved CASP7 and alexa flour-conjugated antigoat and antirabbit secondary antibodies in MCF7 and T47D cell lines. DNA was stained with DAPI.

in other cell cycle proteins examined. In addition, transient siRNA mediated knockdown of *CASP7* mRNA abrogated *CASP7* mediated p21^{Cip} reduction (Figure 8b), suggesting its effect on cell growth and proliferation. *CASP7* has been demonstrated to target p21^{Cip} protein at caspase cleavage motif *DHVDL* yielding fragments with a molecular weight ~12.4 and 6 kDa.³⁸ Therefore, it becomes apparent to investigate whether the p21^{Cip} reduction was due to protein cleavage or transcript level decrease. To address this issue, we isolated total protein and RNA from the *CASP7* overexpressed MCF7 cells and only RNA from siRNA *CASP7* knockdown samples. Interestingly, overexpression and knockdown of *CASP7* did not change the p21^{Cip} mRNA levels (Figure 8c), suggesting that the reduction may be possible only at protein levels (Figure 8a). However, though several attempts were made to detect the cleaved forms of p21^{Cip} in the stripped blots overexpressed with *CASP7* but it was undetected. As *CASP7* expression is E2 dependent and cleaved forms of *CASP7* was detected only in cancerous cell lines and not in MCF10A (Supplementary Figure 4) we next asked a question if E2 treatment or ectopic expression of *ER α* leads to activation of *CASP7* to affect p21^{Cip}. Western blot performed after 48 h of *ER α* transfection and E2 treatment clearly indicates a decreased level of p21^{Cip} protein (Supplementary Figure 2, lane 2, 3, 5, 6). However, we could not detect the cleaved

forms of p21^{Cip} although protein level reduction was observed. No significant change in the activated forms of *CASP7* was seen despite E2 treatment or *ER α* transfection (Supplementary Figure 2) suggestive of activation pathway not dependent on hormone stimulation. Taken together, our results show that *CASP7* downregulates p21^{Cip} at the protein level.

CASP7 and its active forms are localized in the nucleus apart from cytoplasmic region

As *CASP7* downregulates p21^{Cip} to inhibit proliferation and growth of the cells,³⁹ it was worth to detect the localization of *CASP7* in the cells. Earlier reports suggested *CASP7* localization in both cytoplasm and nucleus;^{21,40,41} however, not much is known in the breast cancer cells. To investigate the localization of *CASP7*, we analyzed the TMA data of breast carcinoma, which show presence of *CASP7* in the nucleus apart from cytoplasmic region of the cells to possibly regulate nuclear proteins (Figure 9a). We also performed cell fractionation and antibody staining of *CASP7* protein in breast cancer cells. As shown in Figure 9b, cell fractionation analysis confirmed the presence of *CASP7* in the nucleus with ~30% of the cellular *CASP7* based on western blot data. Confocal analysis showed a punctate-like structure of *CASP7* and its active form in both nucleus and the cytoplasm of MCF7




Figure 10. Effect of broad-spectrum caspase inhibitors and *CASP7* on proliferation and growth of breast cancer cells. **(a, b)** Colony-forming ability of MCF7 and T47D cells after treatment with caspase inhibitors: z-DEVD-fmk (10 μ mol/l) and z-FA-fmk (30 μ mol/l). Growth of cells (> 50 cells/colony) was stained by 0.1% (w/v) crystal violet solution and measured by dissolving the dye with 10% (v/v) acetic acid at 590nm. **(c, d)** Proliferation of breast cancer cells were tested by transient transfection of *CASP7* expression vector (300 ng) and siRNA (100 pmole) in MCF7 and T47D. Transfection efficiency was quantified by western blot with *CASP7* antibody (1:5000, abcam) and α tubulin (1:10000, sigma) was used as an internal control. Proliferation was checked by MTT assay. The data shown (means \pm s.e.) were obtained from three individual experiments. * $P < 0.05$. *** $P < 0.001$.

and T47D cells (Figure 9c). The specificity of immunofluorescent staining and presence of CASP7 and its cleaved forms were confirmed by the lysates fractionated from MCF7 and T47D cells. The cytoplasmic fraction of both the cell lines show a small amounts of active form of CASP7 but not in nucleus, which might be due to low amounts in the nucleus (Supplementary Figure 3). It was also essential to know if the activated forms of CASP7 exist in the nontransformed breast epithelial cell line, MCF10 or only in breast cancer cells. Western blot from the whole-cell lysate from MCF10A and MCF7 clearly suggest the presence of activated forms of CASP7 in the latter but not in MCF10A (Supplementary Figure 4).

Broad-spectrum caspase inhibitors and small interfering mediated CASP7 knockdown affect proliferation and cell growth

We next investigated the effect of peptide inhibitors of CASP7 on proliferation and growth of breast cancer cells. The sensitivity of breast cancer cells to peptide inhibitors, z-DEVD-fmk and z-FA-fmk was checked by MTT assay at a concentration below 100 $\mu\text{mol/l}$. A significant decrease in the growth of breast cancer cells (MCF7 and T47D) was observed at a concentration of 10 $\mu\text{mol/l}$ and 30 $\mu\text{mol/l}$ in case of z-DEVD-fmk and z-FA-fmk-treated cells, respectively, from colony-forming assay (Figures 10a and b). As the peptide inhibitors used also have effect on other caspases apart from CASP7, which are also proved to have a role in proliferation, we performed MTT assay after transient overexpression or knockdown of CASP7. Transient overexpression or knockdown of CASP7 after 48 h showed a significant change in the proliferation of breast cancer cells (Figures 10c and d, upper panels). The increased proliferation of breast cancer cells was reversed upon knockdown of CASP7 (Figure 10d). The overexpression and knockdown of CASP7 was confirmed by western blot (Figures 10c and d, lower panels). Taken together, results from peptide inhibitors and knockdown experiments suggest the probably role of CASP7 in cell proliferation and growth of breast cancer cells.

DISCUSSION

In this paper, we demonstrated that CASP7 overexpression in primary breast carcinoma is ER α dependent and its high expression is correlated with better prognosis. We also provide evidence that CASP7 and its active form are localized in the nucleus apart from cytoplasm and regulate p21^{Cip} expression. Furthermore, inhibition of CASP7 by broad-spectrum peptides significantly reduced the proliferation and growth of breast cancer cells. Therefore, our study proposes that CASP7 may function as one of the factors to contribute breast carcinogenesis.

Elevated levels of CASP7 are seen to associate with moderate and well-differentiated tumors in Oral Squamous Cell Carcinoma.²⁴ Although knockdown or inhibition of CASP7 leads to decreased proliferation and growth of different cancerous cells.^{18,19} Expression studies of CASP7 in breast carcinoma are not much known. A single literature study in primary breast carcinoma showed that expression of CASP7 had no correlation with the rate of apoptosis, suggesting its role other than apoptosis.²² Our studies from Oncomine data sets showed a significant upregulation of CASP7 mRNA expression in BC patients compared with the normal breast tissues, which was further confirmed in breast cancer cell lines. The upregulation of CASP7 expression showed a positive correlation with ER α presence as revealed from Minn *et al.* and Chin *et al.* data sets, which was also confirmed in ER α knockdown cells (Figures 2c and e). Such aberrant expression of CASP7 was also seen in different grades of the breast carcinoma as observed from TMA and Oncomine data sets though with certain variations. Such variations in CASP7 expression were also detected in other cancers,⁴² which might be

due to the genetic and epigenetic factors associated with the disease. Our initial experiments and analyses showed that CASP7 might be involved in breast carcinogenesis. However, the molecular mechanism of the aberrant CASP7 expression in BC is yet unknown. Kaplan–Meier survival curves for relapse-free survival indicated a better prognosis with higher expression of CASP7 in patients with combinatorial endocrine therapy and no survival significance in patients treated exclusively with tamoxifen or in ER-negative BC patients. These findings indicate the potential need for combinatorial therapy in BC patients with high CASP7 expression.

Majority of the breast cancers are ER α dependent (~70%) and E2 driven.^{43,44} Genome-wide analysis of ER α recruitment to the target promoter post E2 treatment demonstrated a wide array of genes regulated directly or indirectly by ER α .^{45,46} Notably, both the genome-wide analysis identified CASP7 as a direct target gene of ER α but its molecular regulation was not well defined. This study provides a novel mechanism underlying E2-mediated CASP7 induction and also its implications in breast cancer cells. All the five putative cis-acting ERE elements in CASP7 promoter had the ability to recruit ER α but only ERE sites, S3 (–328/–341) and S4 (–408/–421) have the potential to regulate E2-mediated ER α transactivation of CASP7 promoter. Distinct effects of E2 on the interaction of ERs with other proteins may lead to differential activity of ERs. ERs belong to a large superfamily of nuclear receptors and share a significant sequence homology with the orphan nuclear receptor.¹² Therefore, cross-talk between the receptors, ER β and ERR β , by binding to the full-length or extended half ERE sites recognized by ER α cannot be ignored.^{12,31,32} In support to this mechanism, increase in ER β and ERR β levels positively regulate the CASP7 promoter during E2 treatment (Figure 5a). ERR β is known to constitutively activate transcription without any ligand.⁴⁷ However, ectopic expression of ERR β in the presence of E2 significantly increased the transcriptional activity of CASP7 probably due to the physical interaction between ER α and ERR β during treatment.⁴⁸ Consequently, the physical occupancy of ER α as a homodimer and with ERR β as a heterodimer in the response element of CASP7 during hormone stimulation is one the major factor for the enhanced CASP7 transcription.

Gene expression is maintained by a critical balance of histone acetylation and deacetylation pattern induced by histone acetyltransferases and HDACs, respectively. Aberrant expression of HDACs is associated with tumor development^{49–54} by inducing altered gene expression linked to proliferation, cell cycle and apoptosis. No significant change in the HDACs levels with E2 treatment was observed. However, certain variation in HDAC expression was observed in breast cancer TMA, which correlated with hormone receptor status.⁵⁵ Moreover, significant upregulation of acetylated H3 and its recruitment along with ER α and p300 in the presence of hormone resulted in pol II occupancy in the CASP7 promoter to increase its transcription. The result was consistent with previous studies in the dorsal hippocampus.^{34,35,56}

Further investigating the role of CASP7 overexpression on cell cycle proteins in breast cancer cells revealed that CASP7 significantly reduced p21^{Cip} levels and not other proteins. This phenomenon was reversed by transient knockdown of CASP7. Earlier reports revealed that CASP7 target p21^{Cip} by cleaving at DHVDL motif (amino-acid positions—109 and 114) consequently yielding fragments with molecular weight 12.4 and 6 kDa.³⁸ Hence, we speculated that p21^{Cip} downregulation during CASP7 overexpression was a result of proteolytic cleavage of the protein and not transcript reduction. Though p21^{Cip} protein level was downregulated with CASP7 overexpression or E2 treatment we are still unsure if it was due to proteolytic cleavage as cleaved forms were not detected after repeated experiments. Although detectable levels of activated CASP7 were observed in breast cancer cells (Figure 9d, Supplementary Figure 2) with little change during hormone stimulation or ER α overexpression might suggest the

mechanism of induction and activation of CASP7 to be an independent phenomena. To our surprise, activated forms of CASP7 in MCF7 cells was detected but not in noncancerous breast epithelial cells, MCF10A (Supplementary Figure 3). Therefore, it will be intriguing to understand whether the active forms of CASP7 are specific to only cancerous cells as observed in our studies. The presence of cleaved forms of CASP7 along with other active caspases has been demonstrated in cervical cancer cell line, HeLa.¹⁸ The upstream activated caspases like CASP8 may be responsible for activating CASP7 in breast cancer cells (data not shown) or HeLa cell line.¹⁸ Though p21^{Cip} levels were decreased after E2 treatment or ER α ectopic expression but it is not clear if the downregulation was mediated through CASP7 as E2 is also known to downregulate p21^{Cip} expression.^{11,57} CASP7 seen to localize in the cytoplasmic and nuclear compartments executes apoptosis by cleaving several endogenous substrates such as p21^{Cip}, p27^{Kip1}, MCM3 and so on.^{58,59} In accordance with previous studies,²² we also observed positive CASP7 staining in both nucleus and cytoplasm in primary breast carcinoma though certain variations were observed. The localization of active form of CASP7 was speculated previously in the nucleus to regulate cell cycle progression, which the authors did not confirm its presence.¹⁹ In our present study we could detect the active form of CASP7 by immunofluorescence in the nucleus of MCF7 and T47D cell lines but its presence was hardly detected in the nucleus during fractionation assay of breast cancer cells, which might be probably due to levels lower in the nucleus than in cytoplasm. However, the localization of active form of CASP7 in the nucleus cannot be ignored as it was observed during immunofluorescence. Active forms of CASP7 have the potential to target p21^{Cip} thereby negatively regulate cell cycle, inhibit cell growth and proliferation through binding to PCNA or inhibition of CDK2 activity.^{60,61}

Overexpression and activation of CASP7 in BC cell lines underlined the possible activation processes facilitated by initiator caspases, CASP8 and CASP9.⁶² The cleavage of poly-(ADP-ribose) polymerase 1, hallmark of CASP3/CASP7 activation⁶³ was not detected despite the presence of activated CASP8 and CASP7 in the BC cells (data not shown). Inhibition of CASP7 by caspase inhibitors- z-DEVD-fmk and z-FA-fmk could significantly decrease the proliferation and growth potential of the breast cancer cells. As the CASP7 inhibitors used were broad-spectrum inhibitors; therefore, offset effect of other caspases cannot be ignored. However, MCF7 cells are CASP3 deficient⁶⁴ and the presence of activated CASP7 in an apoptosis independent manner to downregulate p21^{Cip} suggests its role in proliferation, but our results do not deny the role of other possible caspases in proliferation of breast cancer cells. Altogether, our results advocate the possible role of CASP7 in breast cancer progression by targeting p21^{Cip} that may be considered as an alternative therapeutic target against breast cancer.

MATERIALS AND METHODS

Tissue microarray

BC tissue microarray slide (Cat No. BR1505) was purchased from US Biomax (Rockville, MD, USA) and stained with CASP7 antibody (ab32522, Abcam, Cambridge, MA, USA) as previously described.⁶⁵ The images were captured by Leica (Wetzlar, Germany). The slide was examined and scored by an experienced pathologist. The scoring was performed based on intensity of positive staining and percentage of cells positive for the stain.

Intensity score: 0 – ive, 1+ mild, 2+ moderate, 3+ strong.

Percentage of tumor cell positive: 0–100%.

Cell culture and treatment

MCF7, T47D and MDA-MB231 cell lines purchased from NCCS (Pune, India) were maintained as previously described.⁶⁶ MCF10A, a kind gift from Dr Annapoorani Rangarajan (IISc, Bangalore, India) was maintained as

previously described.⁶⁷ The cells maintained for 48–72 h in phenol-free medium prior to hormone treatments were then treated with estrogen (Sigma, St Louis, MO, USA) at a concentration of 100 nM for 24–48 h. During inhibition studies, MCF7 cells were treated with 10 μ M of tamoxifen and 1 μ M of ICI182,780 (Sigma) for 6 h prior to hormone treatment. To study the direct effect of estradiol in CASP7 expression, MCF7 cells were treated with 10 μ g/ml of cyclohexamide and 5 μ M of actinomycin D (Sigma) for 30 min followed by hormone treatment for 24–48 h.

RNA isolation and quantitative reverse transcriptase PCR

Total RNA was isolated from the cells using Trizol reagent (Sigma). A total of 200 ng of DNase I-digested RNA was used to generate complementary DNA using first strand DNA synthesis kit (Life Technologies, Carlsbad, CA, USA). Quantitative PCR was performed using CASP7-specific primers and glyceraldehyde-3-phosphate dehydrogenase was used as internal control (Supplementary Table 1). $\Delta\Delta$ Ct values were calculated and plotted from three independent experiments.

Plasmids, cell transfection and luciferase assay

For stable knockdown cell line generation, ER α (Sigma) was transfected in MCF7 cells using ICAfectin 441 (Eurogentec, Seraing, Belgium). After 24 h post transfection, the cells were subjected to puromycin selection (2 μ g/ml) (Life Technologies). Transient knockdown of CASP7 was performed by transfecting 100 pmoles of siRNA clusters (CASP7-antisense sequences: 5'-UUUGCUGAAUCCUCAACCC-3', 5'-AUGUUGUACUGAUUGUAG-3', 5'-UUCUUCUCAUGGAGGUGUG-3') (Eurogentec) in MCF7 cells. Universal negative control siRNA (Eurogentec) was used as a mock. siRNAs were transfected by using ICAfectin 442 (Eurogentec). For luciferase assays, MCF7 cells seeded in 24-well plates were grown upto 60% confluency and then transfected with 100 ng of luciferase constructs, 200 ng of the expression vector and 10 ng of the renilla luciferase internal control using ICAfectin 441. Twenty-four hour post transfection, the cells were treated with 100 nM of estrogen or 1 μ M ICI182,780 for additional 20 h. Cells were then lysed and Dual Luciferase assay (Promega, Madison, WI, USA) was performed as per manufacturer's instructions. 3XERE luc, a gift from Dr Doris Germain (Mount Sinai Cancer Institute, New York, USA) was used as positive control for estrogen-stimulation assays. Statistical analyses were carried out by using Graph Pad Prism 5.01 software. Unpaired t-test was carried out to compare between the two groups. P-values < 0.05 were considered statistically significant. The primers used for generating deletion constructs are provided in the Supplementary Table 1.

Electrophoretic mobility shift assay

Electrophoretic mobility shift assay was performed as described previously.⁶⁸ Oligonucleotides with putative ER α -binding sites were synthesized as provided in the Supplementary Table 1. Competition assays included 50–100-fold molar excess of ER α cold consensus oligonucleotide.

Chromatin immunoprecipitation assay

ChIP assays were performed as described previously.⁶⁹ The antibodies used for ChIP assay includes normal IgG mouse (C15400001) or rabbit (C15410206, Diagenode, Seraing, Belgium), ER α (8644) and acetylated histone 3 (9649, CST, Danvers, MA, USA), ER β (2780-1) and ERR β (ab19331, Abcam), p300 (sc-584) and Pol II (sc-899, Santa Cruz, Dallas, TX, USA). The immunoprecipitated DNA samples were PCR amplified using primers mentioned in Supplementary Table 1.

Western blot

Western blots were performed using whole-cell lysates extracted using radioimmunoprecipitation assay buffer and as described previously.⁶⁸ Nuclear and cytoplasmic extracts were fractionated using a CellLytic NuCLEAR Extraction Kit (Sigma) following manufacturer's instructions. Antibodies used include α -tubulin (T5168, Sigma), ER α (8438), cyclin D1 (2978), cyclin D3 (2936), p21^{Cip} (2947), HDAC1 (5356), HDAC2 (5113), HDAC3 (3949), HDAC4 (7628), HDAC6 (7558), acetylated histone 3 (9649), p18 (2896) and cleaved CASP7 (8438, CST), CASP7 (ab32522, Abcam), H3 (sc-8654), p300 (sc-584) and pol II (sc-899, Santa Cruz) and p53 (550832, BD Biosciences, East Rutherford, NJ, USA). Cleaved CASP7 (8438) detects both cleaved and uncleaved CASP7. Images were acquired by using Chemidoc XRS+ molecular 228 imager (Bio-Rad, Hercules, CA, USA).

Western blot images were quantified using Image J software (NIH, Bethesda, MD, USA).

Cell proliferation assay

Cells (5×10^3 cells/well) grown either in Dulbecco's Modified Eagle Medium or Roswell Park Memorial Institute medium 1640 with 10% fetal bovine serum at 37 °C for 24–48 h in 24-well plates. Approximately 300 ng of CASP7 expression vector or vector control was transfected using ICAfectin 441 (Eurogentec). For CASP7 knockdown 100 pmole of siRNA was transfected and Universal negative control used as a mock was transfected using ICAfectin 442 (Eurogentec). Both expression vector and siRNA-transfected breast cancer cells were incubated for another 48 h. After 48 h of incubation, 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromide assay was performed as described previously⁷⁰ and measured at 570 and 620 nm by using Varioskan Flash Multimode Reader (Thermo Scientific, Waltham, MA, USA). Each experiment was performed at least three times in triplicates.

Colony-forming assay

For anchorage-dependent colony-formation assay, $\sim 2.5 \times 10^2$ cell/well were seeded in a 12-well plate (BD Biosciences). MCF7 and T47D cell lines were treated with CASP7 inhibitors at a concentration below 100 $\mu\text{mol/l}$.^{71,72} z-DEVD-fmk and z-FA-fmk at a concentration of 10 $\mu\text{mol/l}$ and 30 $\mu\text{mol/l}$, respectively, was added to breast cancer cells and maintained at 37 °C in a humidified condition of 5% CO₂. Fresh complete growth medium was added with indicated inhibitor concentrations after every 72 h for 8 days. The cells were then washed with PBS (phosphate-buffered saline), fixed with 10% formalin for 10 min and stained with 0.1% (w/v) crystal violet solution for 20 min at room temperature. Excess dye was removed by extensive washing with deionized water and air dried prior to solubilization of bound dye in 100 μl of 10% (v/v) acetic acid. The solubilized dye was measured at 590 nm using Varioskan Flash Multimode Reader (Thermo Scientific).

Immunofluorescence

Approximately 0.3×10^6 cells were seeded in 0.2% (w/v) gelatin (Sigma)-coated glass coverslips. At 60–70% confluency, the cells were washed thrice with $1 \times$ PBS, fixed with methanol/acetone (1:1) and incubated for 30 min to 1 h at -20 °C. Cells were blocked with blocking buffer ($1 \times$ PBS, 0.1% (w/v) bovine serum albumin, 0.3% (v/v) Triton X-100), incubated with corresponding primary antibodies CASP7 (ab32522, Abcam) and cleaved CASP7 (sc-22179, Santa Cruz) overnight and stained with subsequent Alexa fluor secondary antibodies (Life Technologies) for 40 min. The cleaved CASP7 antibody (sc-22179) detects only the cleaved form of CASP7 protein. Cells washed with Tris-Buffered Saline and Tween 20 and stained with DAPI (Life Technologies) were mounted on glass slides with prolong antifade reagent (Life Technologies). Images were obtained by confocal microscope (Leica).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Sujit Suklabaidya and Dr Shantibhusan Senapati for their assistance in TMA related work. SC and BMK were supported by research fellowship from Department of Biotechnology, Government of India.

REFERENCES

- Mester J, Redeuilh G. Proliferation of breast cancer cells: regulation, mediators, targets for therapy. *Anticancer Agents Med Chem* 2008; **8**: 872–885.
- Pike MC, Spicer DV, Dahmouch L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. *Epidemiol Rev* 1993; **15**: 17–35.
- Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. *Breast Cancer Res Treat* 2002; **76**: 27–36.
- Bundred NJ. Prognostic and predictive factors in breast cancer. *Cancer Treat Rev* 2001; **27**: 137–142.
- Allred DC. Issues and updates: evaluating estrogen receptor- α , progesterone receptor, and HER2 in breast cancer. *Mod Pathol* 2010; **23**: S52–S59.
- Clarke R, Skaar T, Leonessa F, Brankin B, James M, Brunner N *et al*. Acquisition of an antiestrogen-resistant phenotype in breast cancer: role of cellular and molecular mechanisms. *Cancer Treat Res* 1996; **87**: 263–283.
- Manni A, Arafah B, Pearson OH. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. *Cancer* 1980; **46**: 2838–2841.
- Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. *Science* 1986; **231**: 1150–1154.
- Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17 β -estradiol-stimulated proliferation of the breast cancer cell line T47D. *Proc Natl Acad Sci USA* 2004; **101**: 1566–1571.
- Wong SC, Chan JK, Lee KC, Hsiao WL. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. *J Pathol* 2001; **194**: 35–42.
- Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. *Proc Natl Acad Sci USA* 2000; **97**: 9042–9046.
- Lu D, Kiriya Y, Lee KY, Giguere V. Transcriptional regulation of the estrogen-inducible p52 breast cancer marker gene by the ERR family of orphan nuclear receptors. *Cancer Res* 2001; **61**: 6755–6761.
- Sengupta D, Bhargava DK, Dixit A, Sahoo BS, Biswas S, Biswas G *et al*. ERR β signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells. *Br J Cancer* 2014; **110**: 2144–2158.
- Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. *BMC Cell Biol* 2013; **14**: 32.
- Lamkanfi M, Kanneganti TD. Caspase-7: a protease involved in apoptosis and inflammation. *Int J Biochem Cell Biol* 2010; **42**: 21–24.
- Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. *J Biol Chem* 2001; **276**: 7320–7326.
- Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C, Martin SJ. Executioner caspase-3 and caspase-7 are functionally distinct proteases. *Proc Natl Acad Sci USA* 2008; **105**: 12815–12819.
- Hashimoto T, Kikkawa U, Kamada S. Contribution of caspase(s) to the cell cycle regulation at mitotic phase. *PLoS ONE* 2011; **6**: e18449.
- Hashimoto T, Yamauchi L, Hunter T, Kikkawa U, Kamada S. Possible involvement of caspase-7 in cell cycle progression at mitosis. *Genes Cells* 2008; **13**: 609–621.
- Matalova E, Lesot H, Svandova E, Vanden Berghe T, Sharpe PT, Healy C *et al*. Caspase-7 participates in differentiation of cells forming dental hard tissues. *Dev Growth Differ* 2013; **55**: 615–621.
- Svandova E, Lesot H, Vanden Berghe T, Tucker AS, Sharpe PT, Vandabeele P *et al*. Non-apoptotic functions of caspase-7 during osteogenesis. *Cell Death Dis* 2014; **5**: e1366.
- Grigoriev MY, Pozharissky KM, Hanson KP, Imyanitov EN, Zhivotovsky B. Expression of caspase-3 and -7 does not correlate with the extent of apoptosis in primary breast carcinomas. *Cell Cycle* 2002; **1**: 337–342.
- Matalova E, Vanden Berghe T, Svandova E, Vandabeele P, Healy C, Sharpe PT *et al*. Caspase-7 in molar tooth development. *Arch Oral Biol* 2012; **57**: 1474–1481.
- Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, Kowalski LP, Soares FA. Caspase expression in oral squamous cell carcinoma. *Head Neck* 2011; **33**: 1191–1198.
- Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H *et al*. Stromal gene expression predicts clinical outcome in breast cancer. *Nat Med* 2008; **14**: 518–527.
- Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. *Breast Cancer Res* 2009; **11**: R7.
- Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A *et al*. X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell* 2006; **9**: 121–132.
- Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL *et al*. Genomic and transcriptional aberrations linked to breast cancer pathophysiology. *Cancer Cell* 2006; **10**: 529–541.
- Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD *et al*. Genes that mediate breast cancer metastasis to lung. *Nature* 2005; **436**: 518–524.
- Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E *et al*. Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. *Biochem J* 2007; **401**: 155–166.
- Pettersson K, Grandien K, Kuiper GG, Gustafsson JA. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. *Mol Endocrinol* 1997; **11**: 1486–1496.

- 32 Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavaillès V, Laudet V. Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). *Mol Endocrinol* 1999; **13**: 764–773.
- 33 Gluzak MA, Seto E. Histone deacetylases and cancer. *Oncogene* 2007; **26**: 5420–5432.
- 34 Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. *Nature* 2009; **459**: 113–117.
- 35 Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B et al. p300 is a component of an estrogen receptor coactivator complex. *Proc Natl Acad Sci USA* 1996; **93**: 11540–11545.
- 36 Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. *Cell Death Differ* 1998; **5**: 997–1000.
- 37 Suzuki A, Shiraki K. Tumor cell "dead or alive": caspase and survivin regulate cell death, cell cycle and cell survival. *Histol Histopathol* 2001; **16**: 583–593.
- 38 Chai F, Evdokiou A, Young GP, Zaleski PD. Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. *Carcinogenesis* 2000; **21**: 7–14.
- 39 Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. *Nat Rev Cancer* 2009; **9**: 400–414.
- 40 Kamada S, Kikkawa U, Tsujimoto Y, Hunter T. Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein (s). *J Biol Chem* 2005; **280**: 857–860.
- 41 MacFarlane M, Merrison W, Dinsdale D, Cohen GM. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. *J Cell Biol* 2000; **148**: 1239–1254.
- 42 Palmerini F, Devillard E, Jarry A, Birg F, Xerri L. Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. *Hum Pathol* 2001; **32**: 461–467.
- 43 Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. *J Mammary Gland Biol Neoplasia* 2000; **5**: 271–281.
- 44 Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. *Endocr Relat Cancer* 2003; **10**: 193–202.
- 45 Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, Siepel AC et al. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. *Mol Cell Biol* 2007; **27**: 5090–5104.
- 46 Laganier J, Deblouis G, Lefebvre C, Bataille AR, Robert F, Giguere V. From the cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. *Proc Natl Acad Sci USA* 2005; **102**: 11651–11656.
- 47 Xie W, Hong H, Yang NN, Lin RJ, Simon CM, Stallcup MR et al. Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. *Mol Endocrinol* 1999; **13**: 2151–2162.
- 48 Bombail V, Collins F, Brown P, Saunders PT. Modulation of ER alpha transcriptional activity by the orphan nuclear receptor ERR beta and evidence for differential effects of long- and short-form splice variants. *Mol Cell Endocrinol* 2010; **314**: 53–61.
- 49 Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. *Breast Cancer Res Treat* 2005; **90**: 15–23.
- 50 Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. *Lung Cancer* 2011; **74**: 300–304.
- 51 Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. *Int J Cancer* 2004; **112**: 26–32.
- 52 Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. *Oncology* 2007; **72**: 69–74.
- 53 Weichert W. HDAC expression and clinical prognosis in human malignancies. *Cancer Lett* 2009; **280**: 168–176.
- 54 Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. *Clin Cancer Res* 2008; **14**: 1669–1677.
- 55 Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer—overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. *BMC Cancer* 2013; **13**: 215.
- 56 Zhao Z, Fan L, Frick KM. Epigenetic alterations regulate estradiol-induced enhancement of memory consolidation. *Proc Natl Acad Sci USA* 2010; **107**: 5605–5610.
- 57 Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. *Mol Cell Biol* 2001; **21**: 794–810.
- 58 Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. *Cell* 1997; **88**: 347–354.
- 59 Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972; **26**: 239–257.
- 60 Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. *Cell* 2007; **129**: 665–679.
- 61 Zhu W, Abbas T, Dutta A. DNA replication and genomic instability. *Adv Exp Med Biol* 2005; **570**: 249–279.
- 62 McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. *Cold Spring Harb Perspect Biol* 2013; **5**: a008656.
- 63 Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? *Mutat Res* 2000; **460**: 1–15.
- 64 Liang Y, Yan C, Schor NF. Liang Y, Yan C, Schor NF. Apoptosis in the absence of caspase 3. *Oncogene* 2001; **20**: 6570.
- 65 Kleiner HE, Krishnan P, Tubbs J, Smith M, Meschonat C, Shi R et al. Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. *J Exp Clin Cancer Res* 2009; **28**: 5.
- 66 Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. *Mol Oncol* 2007; **1**: 84–96.
- 67 Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10 A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 2003; **30**: 256–268.
- 68 Mishra DR, Chaudhary S, Krishna BM, Mishra SK. Identification of critical elements for regulation of inorganic pyrophosphatase (PPA1) in MCF7 breast cancer cells. *PLoS ONE* 2015; **10**: e0124864.
- 69 Listerman I, Sapra AK, Neugebauer KM. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. *Nat Struct Mol Biol* 2006; **13**: 815–822.
- 70 Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L et al. Cell Viability Assays. In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C et al. (eds). *Assay Guidance Manual* 2004.
- 71 Yde CW, Gyrd-Hansen M, Lukkesfeldt AE, Issinger OG, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. *Mol Cancer Ther* 2007; **6**: 1869–1876.
- 72 Wang K, Tang Y, Sun M, Lu B, Zhu H, Ji O et al. The mechanism of neogambogic acid-induced apoptosis in human MCF-7 cells. *Acta Biochim Biophys Sin* 2011; **43**: 698–702.



Oncogenesis is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies this paper on the *Oncogenesis* website (<http://www.nature.com/oncsis>)